Operating as an investment trust since its founding in 2016 in Exeter, United Kingdom, BioPharma Credit PLC concentrates its investments on interest-bearing debt assets. These assets are financially backed by royalties or other revenue derived from the sales of established life sciences products.
Subscribe to see BIOPHARMA CREDIT PLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BIOPHARMA CREDIT PLC is an asset management company headquartered in Riverton, United Kingdom, founded in 2016. Xcout tracks 2 named people at BIOPHARMA CREDIT PLC, including Robert E. Thrailkill (Chairman of the Board, Chief Executive Officer and President).
A few of BIOPHARMA CREDIT PLC's closest competitors — see the full list of competitors and alternatives →
CT Healthcare Trust Plc is a real estate investment trust, which engages in the provision of shareholders with capital growth and income over the long term. The company was founded on October 7, 2016 and is headquartered in London, the United Kingdom.
The Biotech Growth Trust PLC, a closed-ended equity investment vehicle, was originally established by Frostrow Capital LLP and is jointly managed by OrbiMed Capital LLC. Formed on May 20, 1997, and legally based in the United Kingdom, this trust allocates its capital to global public equity markets. Its primary objective is to invest in shares of companies operating within the biotechnology sector, spanning the full range of market capitalizations. The construction of its investment portfolio relies on rigorous fundamental analysis, and its performance is benchmarked against the NASDAQ Biotechnology Index. It was previously identified as Finsbury Emerging Biotechnology Trust PLC.
VPC Specialty Lending Investments Plc operates as an investment vehicle, focusing its capital on opportunities within the specialized finance sector, primarily identifying and pursuing these ventures through digital lending platforms.
Merchants Trust PLC operates as an independent investment fund based in the United Kingdom. Its primary aim is to generate a superior level of income and consistent income growth, alongside sustained capital appreciation, for its investors. To achieve this, the Trust predominantly allocates capital to high-dividend-paying companies listed on the UK FTSE 100 index. The portfolio is broadly diversified across numerous industries, encompassing energy (such as oil, gas, electricity, mining, and multi-utilities), financial services (including banks, life insurance, and real estate investment trusts), healthcare (pharmaceuticals and biotechnology), various consumer sectors (like tobacco, beverages, general retail, and media), infrastructure (construction and materials), telecommunications, and other specialized areas such as travel and leisure, support services, and aerospace and defense.
Schroder British Opportunities Trust PLC operates as a UK-domiciled investment vehicle. Its core strategy involves deploying capital into a blend of both publicly traded and privately held equity stakes, with a strong emphasis on companies based within the United Kingdom.
Established in 2019, Riverstone Credit Opportunities Income Plc maintains its primary corporate office in the United Kingdom.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about BIOPHARMA CREDIT PLC? Suggest a correction
Post the link and the card appears automatically — each network fetches the image itself.